Renal Insufficiency in Treated Essential Hypertension

New England Journal of Medicine

Volumn 320, Issue 11, 1989, Pages 684-688

  Rostand, Stephen G ^a   Brown, Grace ^d   Kirk, Katharine A ^c   Rutsky, Edwin A ^a   Dustan, Harriet P ^b  

^a Division of Nephrology   (United States)

^b Department of Medicine   (United States)

^c Department of Biostatistics ^*  (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE BLOOD LEVEL; ESSENTIAL HYPERTENSION; ETHNIC OR RACIAL ASPECTS; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0024536369     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198903163201102     Document Type: Article

References (31)

1. The 1984 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1984; 144: 1045–57.
2. Thom TJ, Kannel WB. Downward trend in cardiovascular mortality. Annu Rev Med 1981; 32: 427–34.
3. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. 1. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562–71.
4. Hypertension Detection and Follow-up Program Cooperative Group The effect of treatment on mortality in “mild” hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med 1982; 307: 976–80.
5. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028–34.
6. Veterans Administration Cooperative Study Group on Antihypertensive Agents Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213: 1143–52.
7. Mroczek WJ, Davidov M, Gavrilovich L, Finnerty FA Jr. The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 1969; 40: 893–904.
8. Woods JE. Renal function in essential hypertension. Semin Nephrol 1983; 3: 30–9.
9. Mitchell HC, Graham RM, Pettinger WA. Renal function during long-term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension. Ann Intern Med 1980; 93: 676–81.
10. MaGee JH, Unger AM, Richardson DW. Changes in renal function associated with drug or placebo therapy of human hypertension. Am J Med 1964; 36: 795–804.
11. Eggers PW. Effect of transplantation on the Medicare End-Stage Renal Disease Program. N Engl J Med 1988; 318: 223–9.
12. Health Care Financing Administration. Research report: end-stage renal disease 1984. Washington, D.C.: Government Printing Office, 1986:1–70. (DHHS publication no. (HCFA) 03221.)
13. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982; 306: 1276–9.
14. Easterling RE. Racial factors in the incidence of causation of end-stage renal disease (ESRD). Trans Am Soc Artif Intern Organs 1977; 23: 28–33.
15. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the hypertension detection and follow-up program. JAMA 1988; 259: 2113–22.
16. Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly. Lancet 1985; 1: 1349–54.
17. Langford HG, Stamler J, Wassertheil-Smollers S, Prineas RJ. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis 1986; 29: Suppl 1: 29–54.
18. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155–63.
19. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496–507.
20. Shulman NB, Martinez B, Brogan D, Carr AA, Miles CG. Financial cost as an obstacle to hypertension therapy. Am J Public Health 1986; 76: 1105–8.
21. Winickoff RN, Murphy PK. The persistent problem of poor blood pressure control. Arch Intern Med 1987; 147: 1393–6.
22. Feld LG, VanLiew JB, Brentjens JR, Boylan JW. Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment. Kidney Int 1981; 20: 606–14.
23. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993–2000.
24. Hollenberg NK, Borucki LJ, Adams DF. The renal vasculature in early essential hypertension: evidence for a pathogenetic role. Medicine (Baltimore) 1978; 57: 167–78.
25. Guyton achéal, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52: 584–94.
26. Haddy FJ, Pamnani MB. The kidney in the pathogenesis of hypertension: the role of sodium. Am J Kidney Dis 1985; 5: A5–A13.
27. Frohlich ED, Messerli FH, Dunn FG, Oigman W, Ventura HO, SundgaardRiise K. Greater renal vascular involvement in the black patient with essential hypertension: a comparison of systemic and renal hemodynamics in black and white patients. Miner Electrolyte Metab 1984; 10: 173–7.
28. Smith MC, Dunn MJ. Renal kallikrein, kinins and prostaglandins in hypertension. In: Stein JH, Brenner BM, eds. Hypertension: contemporary issues in nephrology. Vol. 8. New York: Churchill Livingstone, 1981:168–202.
29. Luft FC, Weinberger MH, Grim CE. Sodium sensitivity and resistance in normo-tensive humans. Am J Med 1982; 72: 726–36.
30. National Health Survey. Blood pressure levels in persons 18–74 years of age in 1976–80 and trends in blood pressure from 1960 to 1980 in the United States. Washington, D.C.: Government Printing Office, 1986:1–68. (DHHS publication no. (PHS) 86–1684.)
31. Roccella EJ, Bowler AE, Horan M. Epidemiologic considerations in defining hypertension. Med Clin North Am 1987; 71: 785–801.